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Influenza pandemic: the Spanish flu.
‘The world was at war in 1918. Millions of troops were fighting a largely ground struggle in
Western Europe. Influenza was first reported in March 1918 from fort Riley, Kansas, United
States. The virus appeared to have swept the world in three waves over less than two years’
time, gaining virulence with each new assault. Crowding in the military was responsible for
high attack rates reported a month later. Forty percent of US Navy personnel became ill.
There were 54,000 battle deaths among US forces and 43,000 influenza and pneumonia
deaths. By October 1918 its strength was so great that people died with spectacular speed.
Influenza led to cyanosis and death from pneumonia within 2 to 3 days of onset. There were
even reports of women boarding a New York subway feeling little else than mild fatigue and
being found dead when the train stopped 45 minutes later. In New York alone, over 20,000
citizens died. In two months time, 1 in 130 citizens of Philadelphia died from influenza.
Disease was reported across Europe in May, in Africa in June and India and China in August.
In times of steamships and horses influenza had circled the globe in less than 5 months.
Estimates of the total number of deaths worldwide vary from 20 to 40 million leading to
social disruption including a shortage of coffins.’ 
Photo: http://www.pbs.org/wgbh/amex/influenza, accessed March 12th, 2001
Text modified from: Garrett L. The coming plaque. New York: Penguin books USA Inc, 1994 and
Steinhoff M. Epidemiology and prevention of influenza. In: Nelson KE, Masters Williams C,
Graham NMH (eds.). Infectious Disease Epidemiology. Aspen Publishers, Inc.: Gaitersburg,
Maryland, 2001 
2
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Introduction
The burden of influenza
The unique epidemiology of the influenza virus is characterized by winter
epidemics of respiratory disease in temperate climates circulating globally with
attack rates of 10 to 30 percent. In the United States and the Netherlands,
20,000 cases and 2,000 excess deaths occur during influenza epidemics every
year.1,2 Also, the virus has caused three global pandemics in the 20th century.3
Pandemics occur once every 30 to 40 years and the pattern is characterized by a
start from a single location and global spread along the travel routes. Influenza
pandemics are responsible for millions of hospitalizations and deaths worldwide. 
The high mutability of its antigens is the key to its ability of the virus to cause
annual epidemics and periodic pandemics. Influenza A, categorized into
subtypes according to their hemaglutinin (H) and neuraminidase (N)
components, and influenza B are the two main types causing human infections.
Infection occurs in all age groups, but the infection rates are highest among
children, while serious disease and mortality mainly occur among the elderly
and those with high-risk medical conditions, regardless of age.4 
The main transmission route is from person to person by droplet spread
containing up to 105 virus particles/ml.5 The incubation period is short,
averaging two days, and people may be infectious before any symptoms appear.
Uncomplicated influenza is characterized by sudden onset of fever, headache,
cough, myalgia, or other constitutional symptoms.6 Gastrointestinal symptoms
sometimes accompany respiratory symptoms in infants and children. Usually,
influenza is self-limiting, lasting 3 to 5 days. By disruption of epithelia of the
respiratory tract and decreased mucociliary clearance, it can predispose to
complications such as otitis media,7 exacerbations of underlying lung disease8 or
cardiac disease9 and viral or secondary bacterial pneumonia10-12 often needing
hospitalization and sometimes fatal.4 Since the changes in antigenic make-up of
the virus are unpredictable,13 the influenza virus will continue to exact its toll
of morbidity and mortality unless preventive and therapeutic measures targeted
at those who need them are implemented.
Prognosis of influenza 
As preventive health care budgets are limited, large-scale measures for the
control of influenza should focus on individuals with a high probability of
developing complications from it. The available methodology commonly used
to study the prognosis of influenza in the community include cohort and case—
control studies. In the time before large-scale influenza vaccination was
3
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introduced,14,15 or when vaccination rates were still relatively low,16-19 some
studies focused on establishing risk factors for serious outcomes such as need for
hospitalization for influenza and pneumonia, or deaths from all causes during
epidemics. More recent prognostic information has been acquired through
non-experimental vaccine effectiveness studies.20-25 Factors that have
consistently been shown to be independently related to increased risk of such
outcomes include age (notably infants and young children18,19 and the
elderly20-25), underlying disease (e.g. chronic cardiac, pulmonary or metabolic
disease; renal dysfunction; hemoglobinopathies or immune-suppression),4
pregnancy26 and place of residence during epidemics (nursing home or
hospital).27,28
Limitations of current prognostic evidence
Several potential limitations need to be considered when trying to use currently
available prognostic evidence from existing studies in clinical practice. Firstly,
the statistical analyses employed in all studies were incomplete —though most
used logistic regression analysis techniques to assess the independent associations
of potential risk factors with the relevant end point, none extended the analysis
by developing a clinical prediction rule to estimate the probability of an
individual having that end point.29 Data on individual absolute risks of
complications are, however, essential for development of efficient preventive
and therapeutic measures. Secondly, most of these studies were conducted in
North-America. In Europe, general practitioners have a pivotal role both in
delivering health care and in selection of patients for secondary or tertiary care.
The results of the few prognostic studies carried out in European countries21,25
differ from those from North-America.14-20,22-24,26 The absence of studies on
determinants of endpoints other than the serious complications death or
admission to hospital for influenza or pneumonia is another limitation. Some
studies, for example, have shown that during influenza epidemics the
incidences of exacerbations of chronic pulmonary disease,12,30-32 deterioration
of metabolic control in diabetes33 or acute cardiac disease34,35,9 are associated
with the incidence of influenza in the community. However, the risk of these
complications that is attributable to influenza infection is largely unknown. 
Options for the control of influenza 
The main direct option for reducing the impact of influenza is
immunoprophylaxis with conventional inactivated (i.e. killed-virus) vaccine.4,36
Other options include immunoprophylaxis with intranasally administered cold-
adapted live-attenuated influenza virus vaccines,7,37 and use of antiviral drugs
such as amantadine and rimantadine, or neuraminidase inhibitors such as
zanamivir and oseltamivir. The first antiviral drugs are effective against
4
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influenza A only and can cause considerable adverse effects.38 Treatment with
zanamivir39,40 or oseltamivir41 reduces the course of influenza infection by 1 to
1.5 days. Preventive use of these latter neuraminidase inhibitors reduces the
occurrence of influenza illness by 30 up to 89 percent, 42-44 similar effects as the
conventional influenza vaccination in healthy persons.45 Although it might be
expected that prophylactic use of neuraminidase inhibitors increases
protectiveness against influenza when given simultaneously with influenza
vaccination, no effectiveness studies have been carried out among the current
vaccine target population. Another major constraint on using these drugs is the
difficulty of making an accurate diagnosis of influenza in time to be of value.36
In the Netherlands, these drugs are therefore not recommended for large-scale
use for either prophylaxis or treatment. 
Conventional inactivated influenza vaccine
According to the recommendations of the World Health Organization, the
conventional vaccine contains two types A strains and one type B strain forecast
to be the most likely to circulate in the coming winter.4 The current vaccine is
made from virus grown on embryonated eggs. After ultra-centrifugation, virus
particles are highly purified and then killed by formaldehyde. Virus mutation by
antigenic drift and shift means that a new vaccine needs to be developed each
year. The essential data to predict likely new strains are produced by a global
network of surveillance laboratories.46 The development process takes up to six
months which is short enough to prepare for regular epidemics, but too long
for response to a potential pandemic.47 Therefore, other vaccine production
processes are being developed to enable a higher production capacity. 
Influenza vaccine efficacy and effectiveness 
In general, epidemiological studies on the impact of vaccines distinguish two
measures: vaccine efficacy and vaccine effectiveness.48 Vaccine efficacy is
commonly assessed in pre-marketing randomized double-blind placebo-
controlled clinical trials. The most frequently used clinical endpoints in such
trials include post-vaccination protective antibody titers as a measure of indirect
protection and influenza infection rates as a measure of direct protection. Study
populations include healthy people and sometimes patients in a limited range of
high-risk categories. In influenza vaccine trials, most vaccinated children and
young adults developed protective antibody titers against influenza with strains
similar to vaccine components.45,49,50 Some studies suggest that elderly
persons51 and patients with certain chronic diseases52,53 (the most important
subgroup to target for vaccination) may develop lower titers. Only one
randomized placebo-controlled trial has been conducted to establish clinical
direct effects of vaccination among healthy elderly people.54 In this Dutch
5
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study by Govaert et al. the vaccine appeared to reduce the incidence of
serologically confirmed influenza by 50%.    
For overall protective clinical effect in routine clinical practice calculated from
post-marketing studies the term ‘vaccine effectiveness’ is often used. Influenza
vaccine effectiveness is the result of both the vaccine’s direct effect, which
refers to the ability of the vaccine to protect the individual against clinical
influenza infection and its complications, and the indirect effect, which refers to
reduction of the spread of influenza in the population. This latter effect is one
of the reasons to vaccinate persons in closed communities such as nursing
homes,27 health care institutions28 and day-care for children.55 Vaccine
effectiveness can be estimated using post-marketing study designs including
pragmatic randomized controlled trials, cohort and case—control studies
incorporating clinical end points relevant to the individual patient. In cohort
studies, vaccinees and non-vaccinees are followed up retrospectively or
prospectively and incidences of complications of influenza in both exposure
groups are compared. The common measure of association is the incidence rate
ratio which may be considered as a relative risk (RR). In case—control studies,
frequency of exposure, i.e. vaccine use, in cases and controls (randomly
sampled from the study base) is compared. In these case—control studies, the
common measure of association is the odds ratio (OR) or, in case of a matched
design, the ratio of discordant pairs. In general, vaccine effectiveness in percent
is given by 1—RR*100 in trials and cohort studies or 1—OR*100 in case—
control studies.5
In contrast to the scarcity of large randomized placebo-controlled trials with
clinically relevant endpoints, there are many published non-experimental
studies on influenza vaccine effectiveness. Gross et al. have summarized the
results of 20 such studies carried out among the elderly.56 The pooled estimates
of vaccine effectiveness were 56 percent (95 percent confidence interval 39 to
68 percent) for preventing respiratory illness, 53 percent (35 to 66 percent) for
preventing pneumonia, 50 percent (28 to 65 percent) for preventing
hospitalization and 68 percent (56 to 76 percent) in preventing death. One of
the key studies on the vaccine’s effectiveness on severe end points was a serial
prospective cohort study among the elderly by Nichol and colleagues.20 In this
study, more than 25,000 elderly non-institutionalized seniors were followed up
using medical databases during three consecutive influenza periods. The overall
vaccine effectiveness in reducing the incidence rates of death or hospitalization
for pneumonia or influenza appeared to be between 48 and 57 percent. In
another earlier case—control study, Fedson and colleagues observed reductions
in hospitalizations for pneumonia or influenza of between 29 and 32 percent,
6
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and reductions in mortality from all causes of between 27 and 30 percent
among persons aged 45 years or older.23 Another key study published by
Ahmed and colleagues estimated a 41 percent reduction in mortality from all
causes in a case—control study among subjects aged 16 years or older, mostly
elderly.57 Most subsequent studies among the elderly confirmed the vaccine’s
effectiveness in reducing serious complications such as need for hospitalization
for influenza or pneumonia, or death with estimates varying from 40 to 60
percent.22,25,58 
Limitations of current evidence for influenza vaccine effectiveness 
The various limitations in validity and applicability of the results of the existing
studies might, however, have led to sub-optimal clinical guidelines for influenza
control. One of the major drawbacks of non-experimental evaluation studies of
drugs is the potential for ‘confounding by indication’.59 Vaccinees and non-
vaccinees are not randomly selected and in practice these groups differ with
regard to average prognoses. In health care systems with a strong primary care
component, vaccinees tend to have more risk factors than non-vaccinees.
Unadjusted effectiveness estimates might therefore obscure a potential positive
effect of the vaccine or at least underestimate its true protectiveness. Although
most studies have controlled for the presence of these confounding factors by
applying regression techniques, other techniques in the design or data-analytical
phase of the study such as restriction of the study population or the design of a
quasi-experiment using propensity scores60 have not often been used for further
control for residual confounding.
Other validity issues, particularly with case—control studies, include potential
information bias and selection bias.61 The first refers to differing information on
cases and controls regarding the presence of vaccination or prognostic variables.
The use of medical databases greatly reduces such information bias and most
large-scale studies have therefore collected data by review of computerized
patient records. Selection bias may be present when cases or non-cases are
selected on the basis of their vaccination status. To prevent differential selection
of outcomes for vaccinees and non-vaccinees, the case definition should be
strictly applied. Therefore, most studies use death or hospitalization for
influenza or pneumonia as the main endpoints. However, potential invalidity of
study results remains a concern and authors should carefully discuss potential
sources of bias in their study. 
Finally, most vaccine effectiveness studies were conducted among the elderly or
institutionalized populations. Only few were carried out among children with
chronic high-risk disease and they were small, and covered one influenza season
7
01 hoofdstuk 01  25-07-2001  09:32  Pagina 7
only. In studies including infants and children, the vaccine reduced the
occurrence of episodes of otitis media by 40 percent7,62,63 and the number of
febrile influenza episodes among young asthmatics by 49 percent.64 Among the
large group of patients with high-risk disease of working-age no such clinical
benefits from influenza vaccination have been reported so far and studies are
therefore needed.      
Adverse effects of influenza vaccination
The literature on the potential adverse effects of the vaccine is vast. Local
reactions such as soreness at the site of vaccination usually lasting about two
days occur in 10 to 64 percent of patients.4,36 Severe systemic reactions may
occur in patients who are hypersensitive to egg-allergens, so egg
hypersensitivity is a contra-indication to conventional influenza vaccination,
though in practice it is very rare. Although an association with Guillain-Barré
syndrome has been put forward,65,66 this risk, if present, is as low as one in a
million. In all, the conventional influenza vaccine may be considered safe, even
in combination with routine child vaccinations or pneumococcal vaccines.67
Implementation of a population-based influenza vaccination program and
coverage
Epidemiological studies among the elderly and few among high-risk children
have demonstrated a high impact of influenza and clinical benefits of annual
influenza vaccination. Further knowledge on the barriers to implement an
immunization program is required to be able to effectively control its public
health burden.68 To develop and maintain an effective preventive program,
clear clinical guidelines for care-givers are needed.69 As a first step, the Dutch
Health Council followed by the Dutch College of General Practitioners
summarized evidence for the need for control of influenza by annual
immunization against influenza.70 Furthermore, numerous studies on the
acceptance of influenza vaccination among patients have shown that non-
compliance with annual vaccination programs is mainly associated with lack of
personal recommendation by a physician, lack of awareness of the risks of
influenza and fear of adverse effects.71-74 Educational programs are therefore
needed to reach and convince both physicians and high-risk subjects of the
health benefits of vaccination. Finally, logistical problems inherent in vaccine
supplies should be minimized, and selection of high-risk people for vaccination
should be facilitated. In the Netherlands, general practitioners play a key role in
the health care delivery. Almost all Dutch inhabitants are registered with a GP.
Also, more than 80% of Dutch GPs record all patient contacts in computerized
medical records. Facilities for computerized selection of high-risk patients and
administration of the preventive services are therefore easily available. GPs are
8
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thus in a unique position to target preventive care, especially immunization
programs, to those who need it. A small-scale experimental study carried out in
1993 demonstrated that an educational program aiming at GPs to set up a step-
wise influenza vaccination program was successful in increasing influenza
vaccination coverage among their vaccine target population.75 Based on this
study and other educational studies,69,76 the Dutch Ministry of Health, Sports
and Welfare decided in 1995 to provide financial support for a nationwide
preventive program called ‘Tailor-made prevention’ to educate GPs and
facilitate preventive tasks including influenza vaccination.
Outline of this thesis        
The three parts of this thesis aim at filling some essential gaps in our scientific
knowledge on (I) prognosis of influenza, (II) vaccine effectiveness in high-risk
subgroups and (III) effects of implementing a nationwide primary care based
influenza immunization program. 
Part I. Prognosis of influenza
In chapter 2 we aim at identifying prognostic factors for influenza-associated
death and/or admission to hospital in Dutch adults with high-risk medical
conditions who require influenza vaccination. We specifically address the
potential modification by age of associations of patient factors with the end
points among patients of working-age as compared with the elderly. In chapter
3, we describe how a large-scale influenza vaccination monitoring and
evaluation program covering non-institutionalized elderly people in three
geographically disparate Health Maintenance Organizations (HMOs) across the
United States enabled us to develop and validate a clinical prediction rule for
the need for hospitalizations for influenza or pneumonia, or death from all
causes.
Part II. Clinical effectiveness of influenza vaccination 
In chapter 4 we elaborate on ‘confounding by indication’ in non-experimental
evaluation of influenza vaccination as one of the major methodological
problems of using cohort and case—control study designs. We also suggest
some tools to reduce the impact of such bias and illustrate the effects of some of
these options with part of the data from the study described in chapter 6. In
chapter 5 we describe a serial retrospective cohort study aimed at establishing
the potential clinical benefits of annual influenza vaccination among children
with asthma. This study covered the 1995/96 and 1996/97 influenza A epidemics.
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In chapter 6 we present the results of a prospective cohort study among patients
with asthma or COPD aged 18 years or over during the 1995/96 influenza A
epidemic. In this study we determined the occurrence of influenza-associated
morbidity and mortality and clinical benefits of influenza vaccination with
particular emphasis on the potential modification of vaccine effects by age (18
to 64 years versus ≥65 years). In chapter 7 we report our serial prospective
nested case—control study among asthma and COPD patients of working-age
to determine the occurrence of influenza-associated respiratory and cardiac
morbidity and mortality, and the effect of influenza vaccination in reducing
these complications. Study subjects were followed during the 1998/99 influenza
type B epidemic and the 1999/2000 influenza A epidemic. In chapter 8 we
assess the influence of various high-risk medical conditions on the effectiveness
of influenza vaccination among non-institutionalized elderly members of three
large HMOs. The observations of this prospective cohort study covered the
1996/97 and 1997/98 influenza A epidemics in the United States.
Part III. Implementation of influenza vaccination
In chapter 9 we report the collection of baseline data from a random sample of
Dutch GPs before the nationwide introduction of the ‘Tailor-made prevention’
program. In this study we assessed independent characteristics predicting a high
overall immunization rate. In chapter 10 we evaluate whether the introduction
of a computerized influenza prevention module in a general practitioner
information system facilitates the various logistical aspects of the influenza
immunization program in Dutch general practice. In chapter 11 we present data
of an uncontrolled before-and-after trial on the effects of a coordinated
nationwide program called ‘Tailor-made prevention’ that aimed at improving
influenza immunization practice in the Netherlands.
The thesis ends with a general discussion of our findings with respect to
implications for future control of influenza-related morbidity and mortality. In
addition, this last chapter provides suggestions for further study into various
aspects of this major and continuing public health issue.
10
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Essential issues dealth with in this thesis
What is already known? What is largely unknown? Chapter
Part I. Prognosis of influenza
Influenza affects persons of all ages The incidence of complications other than hospitali- 5, 6, 7
zation for influenza or pneumonia, or death
Infection rates are highest among children The occurrence of influenza-associated morbidity 5, 6, 7
and mortality in children and patients with high-risk 
conditions of working-age 
Complications of influenza infection include The extent to which prognostic factors are associated 2, 3
lower respiratory tract infections, acute with rare influenza complications and whether
cardiac disease, diabetes events and death age modifies the associations
Patients with certain medical conditions, The absolute risk of an individual’s developing 3
elderly, pregnant women and people in complications from influenza and whether a clinically
institutions are at high risk for useful prediction rule can be developed
complications of influenza
Part II. Clinical effectiveness of conventional influenza vaccination
Most evidence is acquired through non- Whether ‘confounding by indication’ can be 4
experimental studies. adequately prevented or limited 
Influenza vaccination reduces respiratory The reduction of influenza-associated respiratory 5, 6, 7
illness, influenza and pneumonia hospital- morbidity in high-risk children and patients
izations and death in the elderly by 30% to 50% of working-age 
Influenza vaccination might lead to lower Whether specific high-risk medical conditions 6, 8
protective antibodies in elderly persons or age influence the vaccine’s efficacy
and persons with high-risk medical 
conditions
Part III. Implementation of influenza vaccination
Clinical guidelines are essential for effective To what extent Dutch GPs follow the influenza 9
preventive care vaccination guidelines 
Personal reminders by physicians increase Which practice and organizational characteristics 9
the acceptability of vaccination by the vaccine in Dutch general practice predict optimal 
target group immunization rates 
Immunization practice might efficiently be Whether computerized facilitation modules 10
implemented in primary care effectively increase vaccine coverage 
Educational efforts should focus on Whether a large-scale multi-faceted educational 11
misconceptions about influenza risks and program could succeed in improving
vaccine effectiveness immunization practice in primary care
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Prognostic factors for influenza-associated hospitalization and death during an epidemic 
To predict which patients with current high-risk disease in the community may benefit most
from additional preventive or therapeutic measures for influenza, we determined prognostic
factors for influenza-associated hospitalization and death in a general practice-based case-
control study among this segment of the vaccine target population with high influenza
vaccination rates. In 103 general practices followed during the 1996/97 influenza epidemic,
cases were either hospitalized or died due to influenza, bronchitis, pneumonia, diabetes, heart
failure or myocardial infarction. Age- and gender-matched controls were randomly sampled
from the remaining cohort. Information was collected by review of patient records. In total,
119 cases and 196 matched controls were included. Of the cases, 34%, 25% and 4% were
hospitalized for acute pulmonary and cardiac disease and diabetes, respectively, and 37% died.
Multivariate conditional logistic regression analysis revealed that presence of chronic
obstructive pulmonary disease, heart failure, previous hospitalization, high GP visiting rate
and polypharmacy were independent prognostic factors. Several non-modifiable determinants
can be used to facilitate targeting additional preventive or therapeutic measures at the most
vulnerable segment of the vaccine target group.
Key-words: influenza, vaccine, prevention, general practice, effectiveness, epidemiology
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Influenza continues to cause considerable morbidity and is considered one of
the world’s major killer diseases.1,2 Recently, much attention has been given to
a potentially upcoming influenza pandemic that may result in large numbers of
casualties, especially among those with high-risk medical conditions.3 To
reduce the health and economical burden of influenza infection, use of
inactivated vaccines by vulnerable patient groups is a major topic in preventive
health care policy.4 However, although influenza vaccination rates are reaching
high levels, immunization does not confer full protection.5,6
In order to increase the impact of additional clinical measures against influenza
or its sequelae such as the use of neuraminidase inhibitors or pneumococcal
vaccines, knowledge about patients most likely developing complications of
influenza is indispensable. Physicians should be able to routinely reach patients
at highest risk, even if immunized against influenza, to direct other preventive
or therapeutic regimens.7 Additional studies with the primary objective to assess
clinical determinants of an increased risk of serious influenza-associated
20
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complications among the largest segment of the vaccine target group,
outpatients with current high-risk medical conditions, are therefore needed. 
As part of an ongoing study to assess the effectiveness of a nation-wide
collaborative primary care program to enhance influenza vaccine uptake in the
Netherlands,8 we conducted a case-control study to establish prognostic
indicators for influenza-associated hospitalization and death among adult
patients with high-risk chronic disease given current immunization rates. 
Methods
Setting and design
Our study is part of an evaluation of the nation-wide intervention program
‘Tailor-made prevention’ that was implemented between 1995 and 1997 to
foster population-based prevention of influenza and cervical cancer in Dutch
general practice.8,9 A sample of 56 computerized general practice (GP) centers
using the GP information system ELIAS (SMS Cendata, Wageningen)
involving 103 GPs, participated in the present study. ELIAS has been developed
to support large-scale epidemiological studies in primary care by facilities such
as integration of coded information on disease status, reasons for encounter and
medical prescriptions in the computerized patient records, and search modules
to enable storage of data in a study database.10 Participating GP centers were
spread all over the Netherlands and relevant anonymous data were supplied by
GPs to the data-management center of the Julius Center, University Medical
Center Utrecht. 
We designed a case-control study nested in the primary care centers’ cohort of
adult outpatients with high-risk chronic medical conditions requiring annual
influenza vaccination according to Dutch immunization guidelines.11 In
October 1996, patients with potential current high-risk disease who were
eligible for inclusion into our study were selected by means of a computerized
influenza prevention software module. Details on the module’s stepwise
selection procedures have been described elsewhere.7 In short, patients were
identified using their date of birth and presence of medical disorders was
identified on the basis of relevant entries of ICPC diagnosis codes, ATC
medical drug codes and tags indicating chronic disease in computerized patient
records. Conditions were grouped as pulmonary disease (chronic obstructive
pulmonary disease [COPD], asthma, lung cancer or other pulmonary disease),
heart disease (heart failure, myocardial infarction, valvular heart disease, angina,
21
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and cardiomyopathy), diabetes mellitus, renal disease and other diseases
(including malignant disorders, neurological disease). In November 1996, we
identified a cohort of 18,163 patients with registered codes indicating potential
high-risk disease among the total vaccine target population including healthy
elderly (n=32,425 persons).
Identification of hospitalized and fatal cases during 1996/97 influenza epidemic 
The epidemic period was defined from 23 December 1996 to 16 February 1997
as influenza peak activity was observed between these dates.12 Questionnaires
were sent fortnightly to participating GPs to identify hospitalized or deceased
patients. Study subjects qualified as a case if they were admitted to the hospital
during the epidemic with a primary diagnosis of an acute episode of influenza,
bronchitis, exacerbation of underlying lung disease, pneumonia, diabetes
dysregulation, congestive heart failure or myocardial infarction or if they died
from these causes. After the epidemic the case definition was verified by the
participating GPs. If a specialist certification letter was present at the GP’s
office, a photocopy was obtained. 
Our objective was to establish prognostic factors among the segment of the adult
vaccine target outpatient population with current high-risk disease, regardless of
age. To ensure the presence of current high-risk disease at inception of the
cohort in November 1996, potential cases had to be excluded from the study
population if no registration of GP contact for their chronic condition in the
preceding 24 months was present (so-called ‘inactive patients’) or if they moved
out of the general practice or died before the epidemic (‘ghost patients’).
Verification of current disease and specific diagnosis at baseline until the
beginning of the epidemic was made retrospectively by the GPs in April 1997.
Surveillance of complications during the epidemic resulted in 202 potential cases
identified and screened for eligibility. We excluded 37 patients without chronic
medical conditions at baseline or lack of GP contact before the epidemic and 46
patients because no eligible controls (i.e. with current high-risk disease) were
available for these patients. In all, 119 cases were available for analysis.
Identification of controls
In April 1997, using a computerized sampling schedule, we randomly sampled
three control patients for every potential case from the database with the
remainder of the cohort, matched for age (in the same 5-years age-category)
and sex. Controls were not reported as hospitalized or deceased during the
epidemic. Of the 357 controls that were sampled from the database for the 119
remaining cases, 12 were excluded because no data were available for these
patients. In addition, 149 patients without high-risk disease at baseline, with a
22
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lack of GP contacts or who moved out or died before the epidemic were
excluded, because they, retrospectively, were not part of the cohort, which
resulted in 196 valid controls. 
Measurements in cases and controls
Baseline demographic information on age, gender and health insurance (private
or National Health Service) was collected by data generated using the influenza
prevention module.7 Further detailed information on potential risk factors was
collected retrospectively by review of GP medical records. Presence of
concomitant high-risk disease and previous hospitalization resulting from
complications related to the high-risk conditions in the 12 months preceding
the epidemic was verified by GPs. Use of medical drugs was reported if used
chronically for the conditions and the number of GP consultations during the
preceding year was counted. Immunization of both cases and controls who
complied with the written invitation took place during mass vaccination
sessions at the GP's office in November 1996. In the Netherlands, most
outpatients receive the vaccine through the GP immunization program.8 The
trivalent sub-unit vaccine composition complied with WHO recommendations
and matched well with circulating strains.12 A person was taken to be a
vaccinee for 1996 if the ICPC-code R44.1 (required for reimbursement), was
present in the patient record within two months prior to the start of the
epidemic.7
Statistical analysis
Data entry and univariate analysis were performed with use of the
commercially available statistical package SPSS for Windows (version 9.0).
Distributions of all variables by case and control status were calculated using
descriptive statistics. Univariate analysis included T-tests for continuous
variables and chi-square tests for categorical variables to assess statistically
significant differences between cases and controls. Multivariable conditional
logistic regression analysis for matched case-control studies with EGRET
(Statistics and Epidemiology Research Corporation, Seattle, Washington) was
applied to assess independent associations of potential prognostic indicators with
the outcome parameter. In the modeling procedure, only those variables were
entered in the multivariable model that were associated with the outcome at a
P-level less than 0.20 in the univariate analysis (8 variables in total). Missing data
on an independent variable were considered as absence of the factor. Both
stepwise and backward elimination procedures were used to construct the final
model. Influenza vaccine status was forced into the final model to assess its
potential protectiveness irrespective of statistical significance. As under-use of
vaccines is most common in younger populations,13 we specifically addressed
23
02 hoofdstuk 02  25-07-2001  09:33  Pagina 23
the relative influence of potential prognostic factors in subgroups of high-risk
patients over and under 65 years of age. In a subgroup analysis in age-strata
(<65, ≥65 years), the same variables of the overall final model were forced into
both separate models. Robustness of the models was assessed by the Hosmer-
Lemeshow goodness-of-fit test. Adjusted odds ratios (OR) and their 95%
confidence intervals (CI) were calculated. Vaccine effectiveness was calculated
as 1 minus the odds ratio (as approximation of the relative risk) in vaccinees
times 100 percent.
Results
Mean age of the patient cohort of 18,163 persons was 62 years (SD 18, range
18-102 years) and 49 percent were male. Based on coded entries, cardiovascular
and pulmonary disease appeared present in 36 and 32 percent, respectively,
whereas 18% were registered with various codes indicating more than one
high-risk condition. Diabetes, renal disease and immune-related disease
appeared far less frequent: 12%, 1% and 1%, respectively. 
Of the 119 incident cases, 44 (37%) cases had died, 31 (26%) suffered from an
exacerbation of underlying pulmonary disease, 22 (18%) from heart failure,
eight (7%) from pneumonia, eight (7%) from myocardial infarction, five (4%)
from diabetes dysregulation and in 1 the only diagnosis was influenza. Written
certification of case diagnosis by a specialist was obtained in 49 (41% of cases).
Mean hospital stay was 13 days (95% CI 10-17 days) and appeared equal in
those under and over 65 years. Sixteen (16%) were treated at the intensive care
unit. Mean age of cases and controls was 70 years (SD 14 years) and 55% was
male. The baseline characteristics of cases and controls are summarized in Table 1. 
In multivariate analysis, the following factors appeared to be independently
associated with the outcome in the total study population (Table 2): previous
hospitalization (odds ratio [OR] 1.9; 95% CI 0.9-4.1), ≥5 GP consultations in
the preceding year (OR 2.5; 95% CI 1.3-4.8), polypharmacy (OR 1.3; 95% CI
1.1-1.7 per additional drug), presence of COPD (OR 3.5; 95% CI 1.5-8.3),
heart failure (OR 3.3; 95% CI 1.0-11.2) or more than one high-risk condition
(OR 3.2; 95% CI 1.5-7.2) and NHS insurance (OR 3.7; 95% CI 1.5-8.7).
Influenza vaccination in 1996 had a moderate and statistically non-significant
protective effect (20% reduction of the outcome parameter) after adjustment for
all other prognostic factors in the model. 
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Table 2 also shows results of the subgroup of certified cases and their controls.
Except for the indicator previous hospitalization and NHS insurance, point
estimates of adjusted relative risks are similar or somewhat higher than those
assessed in all cases and controls.  
25
Table 1. Characteristics of cases (n=119) and controls (n=196)
Cases Controls
Characteristic* No. % No. %
Age ≥ 65 years 83 70 120 61
Male 64 54 111 56
NHS insurance 103 87 133 68
Medical history
Asthma/other PD 3 2 13 6
COPD 24 20 30 15
CHF 9 8 7 4
Myocardial Infarction 7 6 17 9
Other CVD 14 12 62 32
Diabetes 12 10 28 14
Other HD - - 4 2
≥1 high-risk disease 50 42 35 18
GP visits 
1-2 26 22 78 40
3-4 20 17 50 25
≥ 5 73 61 68 35
Previous hospitalization 36 30 19 10
No. drugs (mean, SD) 2.8 1.5 3.5 1.5
Vaccine uptake 
1994 72 61 109 56
1995 81 68 127 65
1996 105 88 174 89
* PD = pulmonary disease (tuberculosis, pleurisy, lung cancer); COPD = chronic obstructive
pulmonary disease; CHF = congestive heart failure; CVD = cardiovascular disease (angina
pectoris, chronic ischaemic disease, atrial fibrillation, stroke, paroxysmal tachycardia, cor
pulmonalis, valvular heart disase, pulmonary embolism); HD = high-risk disease (renal
dysfunction, leukemia, multiple sclerosis, hyperthyreoidy); GP = general practitioner; SD =
standard deviation.
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When analyzed according to age, most associations appeared stronger in
patients aged 18-64 years (Table 3). Much stronger associations were observed
for the prognostic factors NHS insurance, presence of COPD and more than
one high-risk condition.
Discussion
Our study showed that routinely obtained clinical information on patients in
the community with chronic medical disorders can be used to predict influen-
za-associated hospitalization and death during epidemics given an influenza vac-
cination rate in these groups as high as 90%. Moreover, the identified
prognostic factors appeared to be even more strongly related to development of
serious complications of influenza in those under 65 years of age. These results
can facilitate reaching most vulnerable patient groups for additional preventive
or therapeutic measures by physicians in both primary and secondary care and
26
Table 2. Prognostic factors for influenza-related hospitalization and death: 
total study population and specialist-confirmed cases and controls are given
Total study population (n = 315) Confirmed cases and controls (n = 129)
Characteristic Cases Controls Adjusted OR Cases Controls Adjusted OR
(n=119) (n=196) (95% CI) (n=49) (n=80) (95% CI)
No. (%) No. (%) No. (%) No. (%)
NHS insurance* 103  (87) 133  (68) 3.7 (1.5-8.7) 42    (86) 55     (69) 3.0 (0.6-13.6)
COPD† 24    (20) 30    (15) 3.5 (1.5-8.3) 9      (18) 13     (16) 5.0 (1.1-23.7)
CHF† 9      (8) 7      (4) 3.3 (1.0-11.2) 5      (10) 4       (5) 9.9 (1.3-73.4)
> 1 high-risk disease‡ 50    (42) 35    (18) 3.2 (1.5-7.2) 23    (47) 13     (16) 5.6 (1.5-21.1)
≥ 5 GP consultations¶ 73    (61) 68    (35) 2.5 (1.3-4.8) 31    (63) 29     (36) 4.1 (1.2-13.9)
Previous 36    (30) 19    (10) 1.9 (0.9-4.1) 10    (20) 7       (9) 1.0 (0.3-4.1)
hospitalization§
No. drugs (x, SD) 2.8  (1.5) 3.5  (1.5) 1.3 (1.1-1.7) 3.4   (1.4) 2.1    (1.4) 1.4 (1.0-1.9)
Vaccinated in 1996†† 105  (88) 174 ( 89) 0.8 (0.4-2.0) 41    (84) 73     (91) 0.9 (0.2-4.6)
* versus private insurance;† versus other high-risk disease; ‡ versus one high-risk disease; 
¶ versus 1-4 GP consultations; § versus no hospitalization;††versus no vaccination in 1996
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such information is important for winter hospital admissions planning. Also,
identified factors may be valuable indicators that should be controlled for in
case of presence of prognostic dissimilarities among exposed and non-exposed
in future non-experimental evaluations of influenza vaccination or anti-influen-
za agents such as neuraminidase inhibitors. 
A limitation of our study is that diagnostic uncertainty in primary care may
have induced biased associations. The case-definition used included various
acute diseases as diagnosed by GPs. Nichol et al. have stressed that the full range
of complications potentially associated with influenza including respiratory, car-
diac and diabetes complications should be taken into account when evaluating
vaccine effectiveness.14 It is, however, unlikely that systematic error resulting
from diagnostic bias in the study base was present since overall point estimates
of associations were similar in the analysis restricted to specialist-confirmed
cases with their controls. Although virological confirmation of influenza virus
infection was not available for cases, we believe that influenza was directly or
indirectly involved in many complications. Limitation of case detection to the
weeks in which influenza A and B were highly epidemic according to reported
27
Table 3. Prognostic factors for influenza-related hospitalization and death in
patients under and over 65 years of age 
18-64 years (n =1 12) ≥65 years (n = 203)
Characteristic Cases Controls Adjusted OR Cases Controls Adjusted OR
(n=36) (n=76) (95% CI) (n=83) (n=120) (95% CI)
No. (%) No. (%) No. (%) No. (%)
NHS insurance* 31    (86) 49    (65) 8.8   (1.1-73) 72    (87) 84     (69) 3.1 (1.6-8.5)
COPD† 10    (28) 14    (18) 15.6 (2.1-120) 14    (17) 16     (16) 2.1 (0.7-6.1)
CHF† 1      (3) -     - 8      (10) 7       (5) 2.6 (0.7-9.4)
> 1 high-risk disease‡ 15    (42) 8      (11) 24.9 (2.8-223) 35    (42) 27     (16) 2.2 (0.9-5.5)
≥ 5 GP consultations¶ 21    (58) 29    (38) 1.1 (0.2-5.7) 52    (63) 39     (36) 3.0 (1.4-6.7)
Previous 15    (42) 8      (11) 6.8 (1.2-39.4) 21    (25) 11     (9) 1.5 (0.6-3.8)
hospitalization§
No. drugs (x, SD) 3.6   (1.6) 2.1   (1.5) 1.4 (1.0-2.1) 3.5   (1.5) 2.4    (1.5) 1.3 (1.0-1.7)
Vaccinated in 1996†† 32   (89) 65    (86) 0.7 (0.1-4.7) 73    (88) 110   (92) 0.9 (0.3-3.0)
* versus private insurance;† versus other high-risk disease; ‡ versus one high-risk disease; 
¶ versus 1-4 GP consultations; § versus no hospitalization;††versus no vaccination in 1996
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incidence of influenza-like illness from Dutch sentinel practices, the temporal
correlation between case-incidence and influenza-like illness during the surveil-
lance period, and the observation that other viruses like the respiratory syncytial
virus may be relatively less prevalent when influenza activity is peaking, support
this contention.12
Our study lacked adequate power to detect a statistically significant reduction in
serious complications resulting from influenza vaccination in this population
with very high vaccination rates. Nonetheless, our data indicate that a 10 to
30% reduction of complications may be achieved with the conventional triva-
lent influenza vaccine. These estimates are in agreement with earlier reports and
tend to underestimate the true reduction of complications resulting from
absence of virological confirmation.14-18
The study domain of our case-control study was limited to patients with cur-
rent high-risk morbidity. Although an age-based influenza vaccine policy was
demonstrated effective and cost-saving,14 we believe that the impact of addi-
tional measures against influenza and its complications can be most effectively
increased through reaching the most vulnerable patients with these conditions.
Our study is unique in that we determined prognostic factors in a non-selected
outpatient group with a high influenza vaccination rate. Nonetheless, our find-
ings are in accord with results of the few earlier studies that provided informa-
tion on clinical determinants of potentially influenza-associated disease although
different populations were examined and influenza immunization rates were
much lower. Ohmit and Monto, for example, estimated similar relative risks in
those with pulmonary or cardiac disease as observed in our study, although
underlying disease was self-reported by patients and aggregated to large disease-
categories.18 Fleming and colleagues observed increased risks for primary care
patients with chronic pulmonary disease, but not for those with cardiac
disease.19 In their study, GP medical records were available for 50% of cases that
were originally identified which may have masked the role or some prognostic
factors we observed in our study. In elderly and those with cardiac, pulmonary
and more than one high-risk disease, Barker et al. observed increased risks of
pneumonia and influenza deaths.20 No information was present, however, on
primary-care based prognostic indicators such as GP visits and previous hospi-
talization. In a large hospital-based study, Glezen and colleagues observed pul-
monary disease being the most important prognostic variable for hospitalization
due to acute respiratory disease as was cardiac disease for death during influenza
epidemics.21 Furthermore advancing age was associated with higher hospitaliza-
tion rates. Paul et al. showed influenza-related febrile illness to be more com-
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mon among patients with pulmonary disease than others, but in patients with
cardiac disease and with previous hospitalization such an increased risk was not
observed.22 In their study, information was collected from clinic charts which
may lack valuable information on other primary care-based factors. 
Among the non-modifiable prognostic factors that were associated with the
case status in our study, few were unexpected. Polypharmacy should be consid-
ered an indicator of severe underlying disease. In the elderly Dutch population,
two-thirds of persons are insured through the National Health Insurance. NHS
insurance status was much more prevalent in cases than controls and is consid-
ered an important indicator of lower social economic status of patients. In addi-
tion, patients with COPD and those with heart failure appeared to be more at
risk than asthmatics or those with other cardiovascular disease including previ-
ous myocardial infarction. Most likely, the condition of these specific patient
groups is most prone to exacerbations resulting from viral infections. In addi-
tion, a high GP visiting rate has been an important prognostic indicator in
many community- and primary care-based studies among various disease cate-
gories.14-16,23 In an earlier influenza vaccine cost-effectiveness study among the
high-risk segment of patients with chronic lung disease we also found that 90%
of hospitalized patients had COPD, heart failure or a high GP visiting rate.23
Interestingly, the same indicators are of particular importance in adult patients
under 65 years. In the elderly, ageing and poorer immunity against viruses are
strongly associated with increased risks for morbidity from influenza whereas in
younger patients underlying disease might mainly be responsible for develop-
ment of complications. This finding supports current immunization recom-
mendations.5,6
In establishing unbiased estimates of clinical effectiveness of preventive meas-
ures and therapy, community-based pragmatic experiments are considered most
rigorous.24 However, scientists face major problems to design such investiga-
tions mainly because of ethical issues, sample size limitations and unpredictabili-
ty of influenza occurrence.25 Therefore, many non-experimental intervention
studies have been carried out.14-18,21,23,25 More are to be expected among dif-
ferent target groups and effectiveness of other anti-influenza agents as newly
developed vaccines as well as prophylactic drugs may be evaluated in the same
way. However, since comparability of prognosis among exposed and non-
exposed at baseline can be fully achieved by randomization only, non-experi-
mental studies are threatened by confounding bias. Clinical and non-clinical
factors may influence vaccine uptake leading to so-called ‘confounding by indi-
cation’.24 Consequently, the validity of study results depends on the availability
of information to control for inequality in baseline prognosis. Information on
29
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prognostic indicators from our study may be used to more validly assess clinical
effectiveness of influenza prevention in non-experimental studies. 
In conclusion, since the health-economic consequences of influenza infection
are considerable, several identified prognostic clinical indicators of increased
risks for serious complications can be used to improve influenza prevention or
early treatment among most vulnerable patient groups. 
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A clinical prediction rule for pneumonia and influenza hospitalization and death during
influenza epidemics
Background Uncertainties among providers and patients about a patient’s risk for serious
influenza associated complications and the potential benefits from vaccination may contribute
to unsatisfactory low influenza vaccination rates. In order to quantify risk for serious
outcomes during influenza seasons, we developed a clinical prediction rule for the probability
of pneumonia or influenza associated hospitalization or death among seniors.    
Methods We developed the clinical prediction rule using data from linked, administrative
databases on 16,280 non-institutionalized and unvaccinated seniors. Validation of the rule was
conducted in five unvaccinated and six vaccinated additional cohorts of more than 11,000
elderly members of three managed care organizations. Using logistic regression analysis, the
following predictors were selected: age, gender, presence of pulmonary, cardiac and renal
disease, dementia/stroke and cancer, number of outpatient visits and hospitalization for
pneumonia and influenza in the previous year. 
Results Reliability of the regression model was good (goodness-of-fit test, p=0.64) and it
discriminated well between those with and without the combined end point (area under the
receiver-operating curve 0.83, 95% CI 0.81-0.85). Validation revealed moderately lower but
acceptable discriminating values between 0.72 and 0.81. The prognostic accuracy of the
prediction rule in the derivation cohort was high when a cut-off sum-score ≥50 points,
reflecting a predicted probability ≥1.0%, is chosen (subjects with end point vaccinated: 89%,
without end point unvaccinated: 51%) while only 50% of seniors would be selected for
vaccination. The influenza vaccine reduced hospitalization or death by 43% (95% CI 39% to
47%) in subjects with a high score (≥50 points). 
Conclusions The prediction rule may be useful to make sure that at risk seniors are
vaccinated and to target additional measures for vaccination to those most likely to benefit. 
Key words: influenza, immunization, elderly, administrative database, epidemiology
Submitted as: Hak E, Wei F, Nordin J, Mullooly J, Poblete S, Strikas R, Nichol KL.
A clinical prediction rule for pneumonia and death during influenza epidemics.
Influenza continues to cause considerable morbidity and mortality worldwide.1
In the United States, it is estimated that influenza is responsible for hundreds of
thousands of hospitalizations,2 tens of thousands of deaths3 and billions of
dollars in excess costs.4 Most of the excess morbidity and mortality occurs
among the elderly. To reduce these consequences of influenza, recommen-
dations include yearly vaccination of vulnerable patient groups.5,6
Although influenza vaccination is effective in reducing morbidity and
mortality,7-10 and cost-saving among the elderly,11 nearly 40 percent of this
34
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target population fail to receive the vaccine each year.5 Vaccination rates for
high-risk persons under 65 are even lower. Uncertainties among providers and
their high risk patients about the risk of serious, influenza related, complications
and benefits of vaccination may contribute to these low vaccination rates.
Recent data from a survey of Medicare beneficiaries, for example, suggest that
lack of awareness of personal risk is among the most common reasons for failing
to receive the influenza vaccine.12
Another recent issue attracted attention to a higher need for individual risk
stratification. In a notice to readers, physicians were urged to identify high-risk
persons because a shortfall of the influenza vaccine was expected for the 2000-
2001 season.13 This might happen more often during coming influenza seasons
and in case of a pandemic a substantial delay or shortfall of vaccine will likely
occur as well in which information on a patient’s risk will undoubtedly be of
use.14
For these reasons a careful risk assessment using an accurate, objective model of
prognosis could help physicians assess risks of individual patients and improve
the decisions about immunization and additional care. We assessed the
prognostic value of clinical information derived from administrative databases of
three health plans to develop a prediction rule for the probability of
hospitalization for pneumonia and influenza and all-cause death during
influenza epidemics among non-institutionalized persons over 65 years of age.
We further demonstrated performance of the model when applied to our
patients and the consequences of its use in future populations.
Methods
Setting 
This study is part of an ongoing collaborative effort between three large
managed care organizations from geographically disparate locations across the
US to pool data derived from their linked medical databases in order to provide
assessments of impact of influenza and the health and economic benefits of
vaccination among members of their health care plans. HealthPartners (HP) is a
nonprofit health maintenance organization with about 890,000 members in
Minnesota and Wisconsin. It offers coverage for 280,000 members through a
staff model HMO, while the other members are covered through a network
HMO model. Kaiser Permanente Northwest Division (KPNW) provides
medical care for nearly 420,000 persons in the Portland, Oregon-Vancouver
and Washington regions. Oxford Health Plans (Oxford) provides health benefit
35
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plans to 1.8 million members in New York, New Jersey, Pennsylvania and
Connecticut. In all, over 3 million members receive medical care from these
health plans. The health plans used protocols specifying the same definitions of
co-morbidity and outcomes and obtained all study data, including baseline
information, vaccination status and outcomes from their linked, administrative
and clinical databases. 
Study subjects 
All members of the three health plans, aged over 65 years as of October 1, 1996
in the first year and October 1, 1997 for the second year, continuously enrolled
for 12 or more months prior to October 1 of each year and non-institutionalized
were included. A large enrollment period was chosen to ensure valid prognostic
information to derive and validate the regression model.15 Institutionalized
patients were excluded because vaccination status was unknown. 
Definitions of potential predictors
After an extensive literature search, we selected 15 clinical characteristics that
possibly could be related to serious clinical outcomes during influenza
epidemics. At baseline, the following potential predictors were included: age,
gender, and a hospitalization for influenza and pneumonia and number of
outpatient visits in the previous year. Underlying disease of eligible subjects was
classified into 11 non-mutually exclusive disease categories according to entries
of relevant codes in the International Classification of Diseases, Ninth revision,
Clinical Modification (ICD-9-CM) in outpatient clinic or hospital databases 12
months prior to October 1 of each year: (1) pulmonary disease (ICD-9-CM
codes 011, 460, 462, 465-466, 480-511, 512.8, 513-517, 518.3 518.8, 519.9,
714.81), (2) cardiac disease (093, 112.81, 130.3, 391, 393-398, 402, 404, 410-
429, 745-746, 747.1-747.49, 759.82, 785.2, 785.3), (3) diabetes/other endocrine
disorders (250-251), (4) renal disease (274.1, 403, 580-591, 593.71-593.73,
593.9), (5) immune-deficiency/organ transplants (042, 079, 279, V08, V42) (6)
non-hematological and hematological cancer (140-198, 199.1, 200-208), (7)
anemia spleen (280-289, 759.0), (8) cirrhosis (571), (9) nutritional deficiencies
(254-255, 259.2, 260-269), (10) dementia/stroke (290-4, 331, 340-1, 348, 438),
and (11) vasculitis/ rheumatologic diseases (446, 710, 714-714.4, 714.8, 714.89,
714.9). 
Influenza seasons and vaccination 
During the 1996-97 and 1997-98 epidemic, influenza activity was widespread in
most US states, exceeding baseline levels for more than 5 consecutive
weeks.16,17 Influenza periods were defined as follows on the basis of Centers of
Disease Control (CDC) surveillance data: Year 1, HealthPartners November
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22, 1996 through May 24, 1997, Oxford: October 5, 1996 through May 3,
1997. Kaiser: November 22, 1996 through March 22, 1997. Year 2,
HealthPartners: December 7, 1997 through March 28, 1998, Oxford:
November 23, 1997 through April 4, 1998, Kaiser: December 21, 1997 through
March 7, 1998. Vaccination rates varied from 39% to 71% during the years in
the different health plans. 
End point 
The combined end point was the occurrence of hospitalization for influenza or,
its main complication, pneumonia (ICD-9-CM codes 480-487) or death from
all causes during the studied influenza seasons.
Model development 
To develop the model, we used the data on all eligible study subjects from the
HealthPartners database that were enrolled in the first season and who were not
vaccinated against influenza (n=16,280). Absence of a characteristic in the
medical database was assumed to indicate no presence of the characteristic
under study and therefore missing values were absent. Age was classified into
the following 5 categories according to exponential increase in risk of
outcomes: 65-69, 70-74, 75-79, 80-89, ≥90. Similarly, the number of outpatient
visits during the prior 12 months was classified into 4 categories: 0, 1-6, 7-12,
≥13. Descriptive statistics as proportions and means (SD) using SPSS for
Windows, version 9.0, (SPSS Inc., Chicago, Illinois, USA) were calculated to
describe baseline characteristics in the two comparison groups (with or without
end point). The construction of the prognostic model started with a univariate
assessment of the prognostic effect of each characteristic separately as given in
terms of odds ratio’s (OR) and their 95% confidence intervals (95% CI) using
logistic regression analysis. In the next stage we used multivariate logistic
regression modeling with a backward elimination procedure to select those
variables that were related to the outcome with a p-value <0.15 as a criterion
for selection. We first used the continuous variables age and number of
outpatient visits to ensure that the selection of the corresponding classified
variables was independent of the choice of the cut-off values. Forward selection
was additionally performed to verify whether any previously deleted potentially
relevant characteristic was incorrectly eliminated from the model. Interaction
between variables included in the model was assessed to determine deviations
from the additivity assumption by including first-order interaction terms in the
final model. For each patient we calculated the individual probability of the
outcome from the final model (predicted probability).     
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Model evaluation 
The reliability of the multivariate logistic regression model derived from the
derivation set was determined by the Hosmer-Lemeshow goodness-of-fit
statistic.18 The area under the receiver-operating-curve (ROC) was used to
assess the model’s discriminative ability.19 The ROC is a plot of the true-
positive rate (sensitivity) and false-positive rate (1-specificity) which is evaluated
for each cut-off point of the predicted probability. The area under the ROC
can be explained as the probability that the logistic regression model will assign
a higher probability of the outcome to a randomly chosen patient with an
outcome (hospitalization/death) than to a randomly chosen patient without
outcome. An area under the curve (AUC) estimate of 0.5 indicates no
discrimination whereas an estimate of 1.0 indicates perfect discrimination.
External validation of the model was performed by comparing the AUC values
across the other 11 cohorts stratified by immunization status (no/yes), site
(1,2,3) and year (1,2).
Development and applicability of the prediction rule
The regression coefficients of the derived multivariate model were used to
construct the prediction rule.20,21 The predicted probability of outcome equals
1/ 1 + e –(LP)  where the linear predictor (LP) = -6.0906 + 0.4681×age-
category + 0.2939×gender + 2.0872×previous P&I hospitalization + 0.3794×
outpatient visits-category + 0.6012×lung disease + 0.1952×heart disease +
0.4135×renal disease/transplant + 0.7273×dementia/stroke + 1.5887×cancer.
For practical interpretation we have chosen to multiply the regression
coefficients by 30 and round them to form the score. All scores indicating the
relative influence of the variable on the occurrence of the combined endpoint
were added to form a sum-score and classified. For sum-score cut-off points the
following test characteristics were calculated: positive predictive value,
sensitivity, specificity, proportion of outcomes missed (1.0-sensitivity) and
proportion of persons selected.      
Vaccine effectiveness 
To assess whether patients with high or low risk score could benefit from the
influenza vaccine, we calculated the vaccine effectiveness for the seniors in both
risk groups using logistic regression. In this analysis, the association of
vaccination status as main explanatory variable with the dichotomous end point
was assessed, independent of other predictors, site and year. Vaccine
effectiveness (VE) was determined as 1- OR times 100 percent.11 Absolute
reduction (AR) per 1,000 vaccinees was calculated as the vaccine effectiveness
(VE) times the incidence of the end point in non-vaccinees.
38
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Results
Of the 16,280 study subjects of the derivation cohort, 399 were hospitalized or
died during that season (2.5%); 122 (0.7%) were hospitalized for pneumonia or
influenza and 287 (1.8%) died from all causes. 
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Table 1. Association of clinical characteristics with hospitalization and death
in derivation set (n= 16,280). Percentages are given, unless stated otherwise
Characteristic Patients Patient Univariate Multivariate P-value
with without Odds ratio Odds ratio*
outcome outcome (95% CI) (95% CI)
(n=399) (n=15,881)
Demographics
Mean age (SD), y 81 (8) 75 (8) 1.8 (1.6-1.9)† 1.6 (1.4-1.8)† <0.001
Female 41 38 1.2 (1.0-1.4) 1.3 (1.1-1.7) 0.008
Prior health 
care use
Previous P&I 16 1 22.4 (16.3-30.6) 8.1 (5.7-11.5) < 0.001
hospitalization
Mean (SD) no. 26 (27) 11 (14) 2.4 (2.1-2.7)† 1.5 (1.3-1.8)† < 0.001
outpatient visits 
Co-morbidity‡
Heart disease 50 24 3.2 (2.6-3.8) 1.2 (1.0-1.5) 0.10
Lung disease 40 14 4.1 (3.3-5.0) 1.8 (1.4-2.3) <0.001
Dementia/stroke 31 9 4.6 (3.7-5.8) 2.1 (1.6-2.7) <0.001
Renal disease 13 4 4.0 (2.9-5.4) 1.5 (1.1-2.1) 0.02
Cancer 12 2 6.8 (4.9-9.4) 4.9 (3.4-7.0) <0.001
Diabetes 19 12 1.8 (1.4-2.3) -
Anemia 24 8 3.7 (2.9-4.7) -
Nutrional def. 5 2 3.7 (2.4-5.9) -
Vasculitis/rheum 3 2 1.3 (0.7-1.3) -
Immunedeficiency 2 1 2.0 (1.0-4.0) -
Cirrhosis 1 0.3 3.1 (1.1-8.7) -
-: p-value >0.15
* Likelihood ratio test (LR): p<.001; Hosmer-Lemeshow Goodness-of-fit test: p=0.65
† odds ratio’s for the corresponding classified variable are given
‡ see methods section for corresponding ICD-9-CM codes
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Mean age was 75 years (SD 8, range 65 to 110 years) and 38% were male. High-
risk co-morbid conditions, e.g. cardiopulmonary disease, were present in 47%
of subjects.
In univariate analysis, all potential predictors appeared more prevalent in
subjects who were hospitalized or died and statistically significant associated
with the combined end point, except for a history of immune-deficiency (see
Table 1). In seniors with the end point, markedly higher prevalence of previous
P&I hospitalization (16% versus 1%), pulmonary disease (40% versus 14%),
dementia/stroke (31% versus 9%) and cancer (12% versus 2%) as compared to
controls was observed.        
Except for the co-morbid conditions diabetes, anemia, nutritional deficiencies,
vasculitis/ rheumatological disorders, immune-deficiency and cirrhosis, all
other variables independently contributed to the multivariable logistic
regression model (table 1). In the modeling procedure, the presence of non-
related diseases did not add to the limited prediction model including age,
gender, previous P&I hospitalization and number of outpatient visits or
predictive value was unacceptably low in the validation cohorts (p>0.15). After
40
Table 2. Area under the receiver-operating-curve (AUC) and 95%
confidence intervals (95% CI) of the clinical prediction rule in validation
cohorts by year, immune status and region
Population Year 1 Year 2
N AUC 95% CI N AUC 95% CI
Non-immunized
Region A 16,280 0.83 0.81-0.85 15,492 0.72 0.69-0.75
Region B 23,914 0.81 0.79-0.84 39,641 0.77 0.76-0.79
Region C 11,775 0.80 0.77-0.82 11,320 0.76 0.73-0.80
Overall 51,969 0.81 0.80-0.82 66,453 0.76 0.75-0.78
Immunized
Region A 24,478 0.79 0.76-0.82 25,019 0.73 0.70-0.76
Region B 15,193 0.73 0.68-0.78 34,846 0.74 0.72-0.76
Region C 31,334 0.80 0.77-0.82 32,136 0.75 0.73-0.77
Overall 71,005 0.78 0.76-0.79 92,001 0.74 0.73-0.76
In gray-shade  is the derivation cohort (n=16,280).
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including first-order interaction terms in the final model, six terms were
statistically significant: gender×dementia/stroke, heart disease×cancer, age×heart
disease, age×hospitalization, lung disease×hospitalization, dementia/stroke×
hospitalization. Although it may be clinically plausible that risks of these
combinations is more than the additive risks of each separate variable, we
decided not to include them in the final prognostic model for three reasons: (1)
these interactions were not observed in earlier studies, (2) they were not
statistically significant in the other external cohorts and (3) they did not
materially contribute to the discriminative value of the model. Performance of
the final model was good (Goodness-of-fit test p=0.65). The model
discriminated well between those with outcome (predicted probability
10%±1%) and those without outcome (0.2%±0.4%). The AUC was 0.83 (95%
41
Table 3. Prediction rule for estimating the probability of hospitalization for
pneumonia and influenza and all-cause death
Characteristic Score*















Renal disease or transplantation +12
Dementia or stroke +22
(Non-)haematological cancer +48
* The sum-score for a given persons can be obtained by summing the scores for each
applicable characteristic. The sum-score correlates with the predicted probability through
the formula (see methods section).  
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CI 0.81-0.85). AUC estimates were moderately lower, but acceptable across the
validation cohorts (see table 2, range 0.72 to 0.81). The average discriminative
power was approximately 0.05 points lower in the second as compared to the
first season and 0.03 points lower in the immunized as compared to the non-
immunized persons.
The prediction rule was derived from the final multivariate model in which a
score was assigned to the presence or level of each variable (table 3). A sum-
score for each patient, reflecting the probability of reaching an end point, was
calculated by adding the scores of relevant characteristics. For instance, the
sum-score for a 66-year old female patient with Hodgkin’s disease who visited
the outpatient clinic 7 times in the previous year and is recently diagnosed with
asthma is 97 (9 + 48 + 22 +18) which is a 25.5 times higher risk than the lowest
risk category (see also table 4).      
The prediction rule can be used to identify those at highest risk for serious
influenza associated complications and those therefore most likely to benefit
from vaccination. Using the derivation cohort, for each cut-off level of the
42
Table 4. Test characteristics of sum-score cut-off points in derivation cohort
(n=16,280)
Sum-score No. OP RR Cut-off PPV SE SP OM Selection
Category (%) (%) point (%) (%) (%) (%) (%) 
≥0-<10 519 (3.2) 0.2 1.0 0 2.5 100 0 0 100
≥10-<20 1153 (7.1) 0.4 2.0 10 2.5 99.7 3.3 0.3 96.8 
≥20-<30 2552 (15.7) 0.2 1.0 20 2.7 98.4 10.5 1.6 89.7
≥30-<40 2371 (14.6) 0.5 2.5 30 3.2 96.9 26.5 3.1 74.0
≥40-<50 1579 (9.7) 1.1 5.5 40 3.9 93.6 41.3 6.3 59.4
≥50-<60 2128 (13.1) 1.2 6.0 50 4.4 89.2 51.1 10.8 49.7
≥60-<70 1787 (11.0) 2.0 10.0 60 5.5 82.8 64.3 17.0 36.6
≥70-<80 1329 (8.2) 2.5 12.5 70 7.1 74.0 75.3 25.8 25.6
≥80-<90 938 (5.8) 4.2 21.0 80 9.2 65.7 83.5 34.1 17.4
≥90-<100 700 (4.3) 5.1 25.5 90 11.6 44.1 89.2 43.9 11.6
≥100 1224 (7.4) 15.4 77.0 100 15.4 46.9 93.4 52.9 7.4
OP: observed probability of outcome, RR: relative risk (<10 points is reference),
PPV: positive predictive value, SE: sensitivity, SP: specificity, OM: outcomes missed
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sum-score we calculated test characteristics (see table 4). A cut-off score of ≥50
had a sensitivity of 89% (1 out of 10 outcomes is missed) while the number of
seniors selected would be halved. Patients with low risk assignment (score<50)
had an observed average probability of 0.5%, those with high risk (≥50) had an
average probability of 4.0%. With increasing cut-off level, the proportion of
non-selected persons would increase, but the proportion of outcomes missed
increases accordingly. Since the benefits of the cut-off value of ≥50 outweighed
the risk of missing disease in the derivation cohort, we showed the practical
consequences of this cut-off value in the different validation cohorts (table 5).
On average, the sensitivity was high (82% to 83% in the non-immunized,  81% to
88% in the immunized) whereas the reductions of selected persons would range
from 40% to 61%. When analyzing the test characteristics for both subsidiary end
points separately, results were similar (not in table). Finally, influenza vaccination
reduced any hospitalization or death by 43% (95% CI 39% to 47%) in persons
with a score ≥50 and 33% (95% CI 24% to 45%) in those <50 points. The
absolute reduction resulting from the vaccine in the high-risk segment of the
population would be 16 per 1,000 vaccinated persons. In other words, only 67
persons have to be vaccinated to save one end point from happening.
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Table 5. Practical implication of using a cut-off score (≥50) in validation
cohorts by year, immunization status, and region. Percentages are given
Cohorts Year 1 Year 2
OP SE OM SP RE OP SE OM SP RE
Non-immunized
Region A* 4.4 89 11 51 50 2.3 81 19 50 50
Region B 3.7 81 19 65 64 3.9 83 17 54 53
Region C 5.5 72 28 70 69 3.0 83 17 56 56
Overall 4.3 82 18 62 61 3.3 83 17 54 53
Immunized
Region A 2.0 87 13 47 46 1.7 83 17 43 43
Region B 1.4 80 20 49 48 2.3 90 10 36 35
Region C 3.1 78 22 64 64 2.0 87 13 44 44
Overall 2.2 81 19 55 54 2.1 88 12 41 40
OP: observed probability, SE: sensitivity, OM: outcomes missed, SP: specificity, RE: reduction
of the target population
* In gray-shade is the derivation cohort (n=16,280). 
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Discussion
This study is unique in that we were able to derive and validate a prediction
rule with acceptable reliability, discriminating ability and generalizibility using
data on large-sized cohorts of seniors from three geographically disparate
located health plans across the US. In comparison with previous prognostic
studies,7-10,22-26 our prediction rule has distinctive strengths. First, we
developed a 9-factor prognostic scoring system in non-selected persons using
information on predictors that can be readily assessed by both patients and
health care providers at any time. Second, patients can be easily assigned to high
or low risk category enabling providers to balance costs and benefits of health
care. Third, the reliability, accuracy and generalizibility of the rule are
supported by derivation in 16,280 seniors and validation in 11 large-sized
external cohorts representing other areas across the United States, different
epidemic season and immunization status.         
The predictors incorporated in our prediction rule have been established in
earlier epidemiological studies.7-10,22-26 Age is a strong predictor for both
respiratory infections, its main complication pneumonia and associated death.27
Males also have been found to be at higher risk than females for influenza
infections.27 Patients with cardiac disease, especially congestive heart failure, are
prone to exacerbations of underlying systemic disorders.28 In addition, the
disseminating potential of influenza infection in the lungs of patients with
chronic respiratory disease is well known.29 Patients with renal transplants30 and
cancer patients receive immune-suppressive medication which put them at risk
for infections.31 Also, previous hospitalization for pneumonia or influenza has
been reported previously as a risk factor.32 Relatively little is known, however,
about the risk of elderly with dementia or stroke. Our results indicate that there
is substantial risk for these persons of dying or being hospitalized during an
influenza epidemic.  
Diabetes was not independently associated with a higher risk of P&I
hospitalization or death in both derivation and validation cohorts. In the
modeling procedure, similar information needed for risk assessment was
acquired through other predictors as age, gender and previous health care use.
It appeared that two-thirds of diabetics had a score ≥50 points and therefore the
disease may be seen as an indicator for high influenza risk which is in
accordance with other studies.33
To our knowledge, this is the first study to demonstrate that risks are not
materially modified by changing epidemics or immunization status. We believe
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therefore that results are applicable to future epidemic seasons. Furthermore,
our prediction rule may be used in non-vaccinated persons, especially those
who have high scores, to efficiently target them for influenza vaccination and
other appropriate medical care whereas in vaccinated persons with high scores,
risk assignment based on the rule help practitioners direct medical care and for
those with low scores avoid unnecessary additional diagnostic, therapeutic or
preventive measures.  
A score ≥50 points represented a high risk with an average expecting occurrence
rate of P&I hospitalization or mortality of 4%. In the derivation cohort, relatively
lower numbers of persons were observed with higher cut-off values while the
numbers of outcomes missed increased substantially. Although we acknowledge
that the proportion of outcomes missed decreases with a lower cut-off score, we
feel that using the cut-off level of 50 points was acceptable in all validation
cohorts whereas the numbers to select for care were reduced to between 40% and
60% on average. From the scoring formula some patient profiles with high risk
can easily be identified on the basis of routine clinical information: e.g. everyone
who has had a previous hospitalization for pneumonia or influenza or a history of
cancer and who is aged over 90 years, and all elderly aged over 80 years with at
least one of the high-risk co-morbid conditions. Since we demonstrated that
influenza vaccination reduced P&I hospitalization or death by 43 percent in
persons with a score ≥50 points, no opportunities should be missed to vaccinate
these persons against influenza and pneumonia.    
For the development of the clinical prediction rule, we studied only persons
aged 65 years and older. The majority of excess deaths and many, if not most, of
the excess hospitalizations for influenza associated complications occur in this
group. However, for many years, persons with high-risk conditions under age
65 have also been included among the high risk groups targeted for vaccination,
and for the 2000-2001 season, the ACIP lowered its age-based
recommendations for annual vaccination down to 50 years.34 How our
prediction rule might apply to these other high-risk groups remains to be seen.
We used pneumonia and influenza hospitalizations and deaths from all causes as
the end points for the prediction rule. These outcomes are highly correlated
and have traditionally been among the main measures used to assess and define
the magnitude and impact of influenza epidemics.1 However, influenza may
also be responsible for a wide range of other complications including
exacerbations of underlying medical conditions leading to increased outpatient
and inpatient health care use.11 It is not clear how the results of our model
might apply to these other outcomes.
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In conclusion, we derived and validated a prediction rule for quantifying the
probability of P&I hospitalization or death with acceptable reliability,
discriminating ability and generalizibility. In addition to the recommendation to
routinely immunize all persons over 50 years of age against influenza, our
prediction rule may help practitioners to target efficiently additional efforts to
those who need preventive and therapeutic measures most.
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Confounding by indication in non-experimental evaluation of vaccine effectiveness: 
the example of influenza vaccination
Randomized allocation of vaccine or placebo is the preferred method to assess the effects of
the vaccine on clinical outcomes relevant to the individual patient. In the absence of phase 3
trials using clinical endpoints, alternative non-experimental designs to evaluate vaccine effects
or safety are often used. The application of these latter designs may, however, lead to invalid
estimates of vaccine effectiveness or safety. Since patients with poor prognosis are more likely
to be immunized, selection for vaccination is confounded by patient factors that are also
related to clinical endpoints. This paper describes several design and analytical methods aimed
at limiting or preventing this confounding by indication in non-experimental studies. In
short, comparison of study groups with similar prognosis, restriction of the study population
and statistical adjustment for dissimilarities in prognosis are important tools and should be
considered. Only if the investigator is able to show that confounding by indication is
sufficiently controlled for, results of a non-experimental study may be of use to direct an
evidence-based vaccine policy.  
Key-words: influenza, vaccine, effectiveness, confounding, methods, observational studies 
Submitted as: Hak E, Verheij ThJM, Grobbee DE, Nichol KL, Hoes AW. Confounding by
indication in non-experimental evaluation of vaccine effectiveness: the example of influenza
vaccination.
The health economic impact of influenza epidemics is considerable.1-3 In most
western countries, the use of inactivated influenza vaccines by vulnerable
patient groups is advocated to prevent complications.4 However, uptake of the
vaccine remains low, especially in those who need it most.4-6 Disbelief in the
vaccine ‘s effects on clinical outcomes relevant to the individual patient may be
one of the major reasons for disappointing immunization rates.3,4,6-8
Effectiveness of influenza vaccination: randomized controlled trials 
The clinical effects of influenza vaccines such as reduction of major
symptomatic events or death should preferably be studied in phase 3
randomized controlled trials (RCT).9 Provided that the sample size is large
enough, randomized assignment of patients to vaccine or placebo enables valid
assessment of vaccine effects through comparing the occurrence of outcomes in
both patient groups with similar prognosis. Such trials can be conducted among
various segments of the patient population and may give insight into positive as
well as negative clinical consequences of immunization in daily practice.
Results of large enough trials in which the primary endpoint is a clinical
outcome rather than a surrogate endpoint (e.g. immune response) provide
52
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crucial information on the true impact of these preventive measures and are
best suited to guide health care decisions.10,11
However, scientists face many obstacles when planning a RCT for clinical
evaluation of influenza vaccines. First and foremost, as the incidence of
influenza-related complications or adverse effects is low these trials would entail
great expense because large numbers of patients are required.1,12 Second,
several influenza seasons may need to be observed as the virulence of circulating
influenza viral types is highly variable and unpredictable.1,6,13 Finally, once the
vaccine has been licensed ethical concerns may be raised to further evaluate its
effectiveness in placebo-controlled studies, especially when persons at high risk
for complications are involved. Because of these limitations, post-licensing or
phase 4 studies evaluating the vaccine’s clinical effectiveness or safety usually use
a non-experimental approach, notably a case-control or cohort design.9 The
vaccine’s effectiveness is interpreted as the percentage reduction in risk of
influenza-associated complications attributable to vaccination, given in percent
by 1-RR in cohort studies or 1-OR in case-control studies.3 The main
difference between experimental and non-experimental designs lies in the
absence of random allocation of the intervention, e.g. vaccination, by the
investigator. 
Effectiveness of influenza vaccination: non-experimental studies
One of the major problems encountered in non-experimental evaluation of
intended drug effects is the ‘natural’ presence of incomparability of prognosis
among subjects receiving the drug and those who do not.14 In non-
experimental influenza vaccine studies, the vaccine group typically comprises
patients with more severe disease or (perceived) higher risk, either as a result of
self-selection or physician preference, than the non-vaccinated (control)
group.15,16 In contrast, those with a contra-indication for the intervention will
usually be found in the control group only. Thus, selection of exposure is
confounded with patient factors, both clinical and non-clinical, that are also
related to (detection of) the outcome. This phenomenon may equally apply to
qualitative (absence/presence) as well as quantitative (dosing schedule) aspects
of exposure and is usually referred to as ‘confounding by (contra-)indication’ or
‘channeling’.14,17,18 Crude, unadjusted, results of non-experiments may
therefore lead to invalid inference regarding influenza vaccine effectiveness and
potential side effects, i.e. underestimation of both beneficial and adverse effects
in most circumstances. The obligation of the investigator is to design and
analyze the study in such a way that reduction or removal of this type of bias
can be achieved. 
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Prevention of confounding by indication: study design issues
Preventing or limiting confounding by indication can be achieved in the design
and data-analytic phase of case-control and cohort studies (see also Table 1). In
designing a non-experimental study of vaccine effectiveness, valid inferences on
preventive effects can be drawn in those situations in which patient groups are
compared who have similar indications but have undergone different
interventions. These designs could be viewed as ‘natural experiments’.
Hypothetically, patients receiving the influenza vaccine because their general
practitioner (GP) believes in it and is able to organize the intervention program
(intervention group) could be compared with a group of patients listed with a
GP who does not immunize his patients against influenza (control group). Such
comparison groups may however be difficult to identify in one health care
system. Another, less preferred, design option constitutes an ecological study in
which vaccine effects among patients residing in different areas are compared.
Similarity of ecological comparison groups highly depends on distribution of
patient characteristics in different areas. In this respect, a design in which the
incidence of influenza-associated complications of a historical control group of
patients before the introduction of the influenza vaccine is compared with the
incidence of such complications in patients after its introduction (intervention
group) in one area may be a better option. Such a design, however, risks the
incomparability of influenza seasons. 
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Table 1. Methods to reduce confounding by indication 
Design methods
• Comparison of groups with similar prognosis 
(e.g. ‘natural experiment’ or use of historical controls)
• Restriction or stratification of study population 
(e.g. age-strata, gender, current/inactive disease)
• Individual matching of exposed and non-exposed into main prognostic strata
(‘quasi-experiment’)
Statistical methods 
• Statistical control of  confounding factors in multivariable regression model
• Subclassification of patients on levels of the propensity score
• Pseudo-randomization on levels of instrumental variables
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Alternatively, the study domain could be restricted to patients with a more or
less similar prognosis such as institutionalized elderly patients.19 Strict admission
criteria could however limit the generalizibility and applicability of results to
other segments of the population, while incomparability of comparison groups
and residual confounding may persist. Stratification of the study population on
levels of important confounding variables, like for example age, and within
stratum comparisons also enhances internal validity.20
Another option consists of individual pair-matching of vaccinated and non-
vaccinated subjects within strata of important prognostic variables sometimes
referred as ‘quasi-experiment’. This technique was used in a non-experimental
evaluation of the effects of placement of ventilation tubes and proved to reduce
confounding bias.21 The design of a quasi-experiment is, however, costly as it
requires sufficiently large numbers of patients within each stratum. Except for
restriction and stratification, to our knowledge none of the other design options
mentioned above has been applied in non-experimental evaluation of currently
used influenza vaccines. 
Prevention of confounding by indication: data analytical issues
Independent of the study design, statistical adjustment for dissimilarities in
prognostic factors between the patient groups receiving and not receiving the
vaccine can be applied to enhance validity.1,3,22-24 A prerequisite is that valid
and precise data are obtained through the design used to estimate the patient’s
prognosis without too many missing data. In other words, to optimize statistical
adjustment, the prognosis of each patient should be measured by as many valid
indicators as possible to allow adjustments afterwards. In primary care, for
example, the presence of current disease as indicated by presence of GP
consultations in the year preceding the study, also referred as ‘active patient’, is
essential to allow valid adjustment of potential confounding. In the ideal
situation in which all prognostic patient features can be measured, the exact
degree of bias can be quantified and used to draw valid conclusions from the
data. In practice, this is usually impossible due to cost restrictions and difficulty,
and in that case residual confounding or hidden bias can not be ruled out.
However, although in many non-experimental studies residual confounding
may be present, it can be shown that there are limits to the extent of
mathematical explanation by this unmeasured confounding. Its putative effects
mainly depend on the expected prevalence of the unobserved variable(s), and
its associations with vaccination and outcome. Investigators should therefore
always reflect on the potential magnitude of the impact of such bias on the
effectiveness estimate for example by using sensitivity analysis.16,26
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In general, three main methods for statistical adjustments can be applied: (1)
statistical control of confounding variables in a multivariable regression
model;14,18 (2) sub-classifying or matching patients on levels of a so-called
‘propensity score’ 16,25-27 and (3) the use of an instrumental variable to enable
statistical pseudo randomization and to account for any residual confounding.28
The first option is commonly used and comprises several steps: identification of
confounders in the data-set, univariate stratification of exposure groups on
levels of the confounder to estimate the vaccine effectiveness estimate adjusted
for this single variable (e.g. age) and multivariable control including
confounding variables that collectively influence the estimated relationship
between exposure and outcome in the modeling procedure. 
A method to optimize statistical adjustment for confounding by indication in
non-experimental studies, notably when the number of prognostic variables is
large, has been proposed by Rubin and Rosenbaum. They introduced the
‘propensity score’ method.16,25-27 This score is the conditional probability of
exposure to a treatment given a set of observed variables that may influence the
decision to vaccinate. The propensity score can be derived from a multivariable
logistic regression analysis in which those variables that are statistically
significant associated with exposure (e.g. vaccination) are included. Obviously,
the outcome variable should not be included as a co-variate. A higher score
indicates a higher probability of receiving the vaccine. Sub-classification of
subjects on levels of this single variable or including this variable as a single co-
variate in a multivariable regression model tends to balance all of the observed
variables, but not the unobserved.16,25,27 The use of this score and matched
sampling will also implicitly incorporate any interactions among confounders.
Thus, this technique enables the investigator to assess the association of
vaccination with specific outcomes in patients with a more or less equal
probability of receiving the vaccine. Discriminant matching for multivariate
normal co-variates as described by Cochran29 and the use of a ‘confounder
score’ as proposed by Miettinen are related techniques.30
To overcome the potential lack of balance on unobserved prognostic indicators
(e.g. health behavior), the instrumental variable method has been suggested.
This technique originates from the field of econometrics and has so far not been
extensively used in medical research. In short, patients are subdivided according
to levels of a co-variate that is associated with the exposure, but not associated
with the outcome. This pseudo-randomization may lead to equal distribution
of health characteristics in both non-exposed and exposed people and thus
prevent potential confounding. For example, McClellan et al. calculated the
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distance to the hospital on the basis of zip-codes and divided patients into those
living within a small area around the hospital and those outside that area in a
study on cardiovascular procedures.28 Distance to the hospital did fulfill the
criteria for instrumental variables. Heart catheterization was more prevalent in
the inner circle than the outer circle, and mortality rates were similar. This was
in contrast with their prior finding using conventional control for confounding
in which mortality rates appeared higher in patients who underwent the
surgical procedure. Since the validity of this latter method should be evaluated
in other medical studies and instrumental variables may be hard to identify, we
will not further elaborate on this statistical procedure.   
The presence of confounding by indication in non-experimental evaluation of
influenza vaccination and some of the above-mentioned tools to reduce its
impact are discussed in more detail on the basis of data derived from a recent
study by our group. 
An example: Influenza vaccine effectiveness in adult patients with pulmonary
disease  
We examined the effect of influenza vaccine on the incidence of influenza-
associated complications in 1,696 adult patients with chronic obstructive
pulmonary disease (COPD) or asthma during the 1995/96 influenza A
epidemic.31 The study was a one-season prospective cohort study using the
medical database of the Utrecht General Practitioners Network. GP patient
records were reviewed for all study subjects. As a first design approach to limit
confounding by indication, vaccinated and non-vaccinated patients with
pulmonary disease were compared rather than vaccinated patients and controls
from the community. The study population was restricted to those with an
indication for vaccination according to the guidelines of the Dutch Health
Council. In table 2 we give crude and adjusted effectiveness estimates using the
conventional control of confounding by multivariable logistic regression
analysis. In spite of restriction of the study population, crude results appear to
suggest that the vaccine is ineffective and may even lead to complications (odds
ratio (OR) 1.14). However, further statistical adjustments notably for age,
disease and GP visits resulted in striking changes of the effectiveness estimate to
a relative risk of 0.76 suggesting an overall vaccine effectiveness of 24 percent in
this population —a relative parameter change of 33 percent. Addition of other
co-variates in the final model did not substantially change the vaccine
effectiveness estimate.
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Table 2. Crude and adjusted odds ratio’s for an acute episode of low
respiratory tract or cardiac disease or death during an influenza epidemic  in
vaccinees and non-vaccinees
Study population and analysis Adjusted for: Odds ratio 
(95% CI)
Adult patients (18-102 y, n=1696) Crude value: 1.14 (0.84-1.55)
Conventional control: MLR*
+ age (in years) 0.87 (0.64-1.20)
+ disease (asthma/COPD) 0.82 (0.59-1.13)
+ GP visits (in number) 0.76 (0.54-1.05)
+ remaining factors 0.76 (0.54-1.06)
Elderly patients (65-102 y, n=630) Crude value: 0.57 (0.35-0.93)
Conventional control: MLR*
+ age (in years) 0.56 (0.35-0.92)
+ disease (asthma/COPD) 0.53 (0.32-0.87)
+ GP visits (in number) 0.50 (0.30-0.83)
+ remaining factors 0.50 (0.29-0.83)
Younger patients (18-64 y, n=1066) Crude value: 1.27 (0.84-1.94)
Conventional control: MLR*
+ age (in years) 1.11 (0.73-1.70)
+ disease (asthma/COPD) 1.08 (0.70-1.66)
+ GP visits (in number) 0.94 (0.61-1.47)
+ remaining factors 0.94 (0.60-1.45)
Quasi-experiment (18-64 y, n=676) Matched crude value: 0.90 (0.53-1.52)
Conventional control: MCLR**
+ age/ disease/GP visits/ 0.89 (0.52-1.54)
remaining factors
Younger patients (18-64 y, n=1066) Matched crude value: 0.87 (0.56-1.35)
Propensity score + MCLR**
+ age/ disease/GP visits/ 0.86 (0.55-1.35)
remaining factors
* MLR: Multivariable logistic regression analysis; 
** MCLR: Multivariable conditional logistic regression
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Most probably the adjustments were still incomplete. More precise
measurements of disease severity such as pulmonary function, atopy or hyper-
reactivity were not available. Therefore, a second approach to limit
confounding consisted of subdividing the whole study population into two age-
strata (≥65 years, 18-64 years) in which prognosis of vaccinees and non-
vaccinees within each age-stratum is less deviant (see also table 2). Apart from
issues of modification of the effects of the vaccine by age, which is beyond the
scope of this article, with this approach, statistical adjustments for the same
confounding factors resulted in smaller relative parameter changes of 12 and 26
percent, respectively, in both age-categories. This suggests that stratification or
age-restriction may further reduce residual confounding. Still, inferences on the
two age subgroups should be made with caution. In the elderly, a substantial
and statistically significant reduction in the outcome rate was observed even
without controlling for confounding (OR 0.57, 95% confidence interval [CI]
0.35-0.93). Addition of prognostic factors into the multivariate model led to a
further increase in the estimate of vaccine effectiveness indicating some residual
confounding after stratification. However, in the working-age adults the crude
odds ratio was well above 1.0 and despite adjustment for the available
prognostic indicators we could not demonstrate a significant reduction (OR
0.94, 95% CI 0.60-1.45). This suggests that results of restricted populations are
not necessarily applicable to other segments, in this case younger patients.
Because Neuzil and colleagues showed considerable impact of influenza in a
younger group of women6 and we have shown that in the Netherlands the
current influenza target group comprises at least 40 percent of high-risk persons
under 65 years of age,32 we further examined potential confounding in this
particular age-group.
As a third approach to limit potential confounding by indication in the original
design, we used the data of this younger age group (18-64 years) in a ‘quasi-
experiment’. First, we identified the three main prognostic factors: age (5-years
age-category), underlying pulmonary disease (asthma or COPD) and GP
visiting rate (0, 1-2, and ≥3 visits). Next, we classified each subject, vaccinated
or non-vaccinated, into one of the 54 combinations of these factors. Within
each stratum we then randomly sampled from either the vaccinated or the non-
vaccinated group as many patients as were available in the comparison group
with the lowest number of subjects. For example, if 5 vaccinated and 2 non-
vaccinated patients were between 20 and 24 years old, had asthma and
consulted the GP 5 times in the preceding year, we sampled 2 patients at
random from the exposed group to form a stratum matched group. In all, 390
patients (37%) were excluded from the original study population (n=1066) and
676 patients were available for the quasi-experiment. After this matching
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procedure it appeared that the vaccine reduced the occurrence of outcomes by
11 percent, after adjustments for the main confounders and remaining co-
variates (i.e. health insurance, gender), but the estimate was not statistically
significant (see table 2). Only minor changes were observed after statistical
adjustment, suggesting that confounding by differences in the known
prognostic factors was largely removed. A major limitation may prohibit the use
of the above-mentioned ‘quasi experiment’. Pair-matching is time-consuming
and can considerably reduce the power of the study as numbers of matched
patients in separate strata become small. In our example 37% of the initial study
population had to be excluded. To avoid these issues, we finally applied
analytical control of confounding by using the ‘propensity score’. 
In our example, we used the 1066 patients aged between 18 and 64 years to
calculate the probability score of being vaccinated. Our final multivariable
logistic regression model with the dependent variable vaccination included age,
underlying disease, number of GP visits, gender and health insurance. We then
categorized the propensity score into quintiles and matched vaccinees and non-
vaccinees on levels of the probability to be vaccinated. In the multivariable
conditional logistic regression analysis we matched on the categorized levels of
the score and calculated crude and adjusted odds ratio’s of vaccination for the
outcome. The overall adjusted odds ratio of 0.86 appears to suggest a 14%
reduction of complications resulting from the vaccine. The finding of the
‘quasi-experiment’ in which stratum-matched pairs of vaccinees and non-
vaccinees were compared was validated by this statistical method. As was
expected, 95% confidence intervals were smaller, but point estimates were
nearly the same. The latter techniques changed the effectiveness estimate from a
crude estimate of –27% in the original design to 11% and 14% using the ‘quasi-
experiment’ and ‘propensity score’, respectively; relative parameter changes of
more than 30%. In addition, the propensity score method resulted in slightly
smaller 95% confidence intervals than the conventional adjustment. Although
our study lacked adequate power to demonstrate a statistically significant
reduction of outcomes resulting from the vaccine, the adjusted effectiveness
point estimates are compatible with a statistically significant 11% reduction of
outpatient visits for respiratory disease in elderly lung patients as observed by
Nichol and colleagues.33
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Conclusion
Randomized allocation of vaccine or placebo is the preferred method to assess
the effects of the vaccine on clinical outcomes relevant to the individual
patient. In the absence of phase 3 trials using clinical endpoints, alternative non-
experimental designs to evaluate vaccine effects or safety are often used. The
application of these latter designs may, however, lead to invalid estimates of
vaccine effectiveness or safety. Since patients with poor prognosis are more
likely to be immunized, selection for vaccination is confounded by patient
factors that are also related to clinical endpoints. This paper describes several
design and analytical methods aimed at limiting or preventing this confounding
by indication in non-experimental studies. In short, comparison of study groups
with similar prognosis, restriction of the study population and statistical
adjustment for dissimilarities in prognosis are important tools and should be
considered. Only if the investigator is able to show that confounding by
indication is sufficiently controlled for, results of a non-experimental study may
be of use to direct an evidence-based vaccine policy.  
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